Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS

N/ACitations
Citations of this article
N/AReaders
Mendeley users who have this article in their library.

Abstract

Background: In this paper we describe a novel method to achieve high yield bacterial expression of a small protein domain with considerable therapeutic potential; Domain I of Beta-2-glycoprotein I (β2GPI). β2GPI is intrinsic to the pathological progression of the Antiphospholipid Syndrome (APS). Patients develop autoantibodies targeting an epitope located on the N-terminal Domain I of β2GPI rendering this domain of interest as a possible therapeutic. Results: This new method of production of Domain I of β2GPI has increased the production yield by ~20 fold compared to previous methods in E.coli. This largely scalable, partially automated method produces 50-75 mg of pure, folded, active Domain I of β2GPI per litre of expression media. Conclusion: The application of this method may enable production of Domain I on sufficient scale to allow its use as a therapeutic. © 2015 McDonnell et al.

Cite

CITATION STYLE

APA

McDonnell, T., Pericleous, C., Laurine, E., Tommasi, R., Garza-Garcia, A., Giles, I., … Rahman, A. (2015). Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnology, 15(1). https://doi.org/10.1186/s12896-015-0222-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free